PMID- 38435682
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240305
IS  - 2253-5969 (Print)
IS  - 2253-5969 (Electronic)
IS  - 2253-5969 (Linking)
VI  - 11
DP  - 2024
TI  - Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus 
      Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma 
      with a Diameter >8 Cm: A Retrospective Study.
PG  - 399-409
LID - 10.2147/JHC.S439001 [doi]
AB  - PURPOSE: Local in combination with systemic therapy might be an option for 
      patients with advanced unresectable hepatocellular carcinoma (uHCC). This study 
      examined the clinical benefits and adverse events (AEs) of first-line 
      transarterial embolization (TAE) and hepatic arterial infusion chemotherapy 
      (HAIC) combined with atezolizumab (Atezo) and bevacizumab (Bev) in patients with 
      uHCC of a diameter larger than 8 cm. PATIENTS AND METHODS: This retrospective 
      study included patients with uHCC of a diameter larger than 8 cm who were treated 
      with first-line Atezo-Bev and TAE+HAIC at the First Affiliated Hospital of Sun 
      Yat-Sen University between September 30, 2019, and September 30, 2022. 
      Progression-free survival (PFS), overall survival (OS), tumor response according 
      to mRECIST, and AEs were analyzed. Multivariable Cox analyses were performed to 
      examine the factors associated with PFS. RESULTS: Thirty patients were included. 
      The objective response rate (ORR) was 74.4% (95% confidence interval [CI], 
      59.3%-89.5%), and the disease control rate (DCR) was 93.3% (95% CI, 85.4%-98.6%). 
      The median follow-up was 11.4 (inter-quartile range [IQR], 5.5-17.9) months. The 
      median PFS was 6.8 (95% CI, 2.6-11.1) months. The 3-, 6-, 9-, and 12-month 
      survival rates were 86.2%, 82.5%, 68.6%, and 60%, respectively. The median OS was 
      not estimated. Extrahepatic metastasis was independently associated with PFS 
      (hazard ratio [HR]=3.468, 95% CI, 1.001-12.023). The most common AEs were fever 
      (46.7%). Grade 4 AEs occurred one time as hematemesis but no 5 AEs were observed. 
      CONCLUSION: Atezo-Bev combined with TAE and HAIC might benefit patients with uHCC 
      of a diameter larger than 8 cm, with manageable AEs.
CI  - (c) 2024 Cai et al.
FAU - Cai, Hongjie
AU  - Cai H
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, 510062, People's Republic of China.
FAU - Chen, Song
AU  - Chen S
AD  - Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University 
      Cancer Center and Sun Yat-Sen University State Key Laboratory of Oncology in 
      South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, 
      510060, People's Republic of China.
FAU - Wu, Zhiqiang
AU  - Wu Z
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, 510062, People's Republic of China.
FAU - Wang, Fan
AU  - Wang F
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, 510062, People's Republic of China.
FAU - Tang, Shuangyan
AU  - Tang S
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, 510062, People's Republic of China.
FAU - Chen, Ludan
AU  - Chen L
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, 510062, People's Republic of China.
FAU - Guo, Wenbo
AU  - Guo W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Sun 
      Yat-Sen University, Guangzhou, 510062, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20240226
PL  - New Zealand
TA  - J Hepatocell Carcinoma
JT  - Journal of hepatocellular carcinoma
JID - 101674775
PMC - PMC10906278
OTO - NOTNLM
OT  - immune checkpoint inhibitors
OT  - large unresectable hepatocellular carcinoma
OT  - local therapy
OT  - systemic therapy
OT  - tyrosine kine inhibitors
COIS- All authors declare that they have no competing interests in this work.
EDAT- 2024/03/04 06:48
MHDA- 2024/03/04 06:49
PMCR- 2024/02/26
CRDT- 2024/03/04 05:04
PHST- 2023/09/06 00:00 [received]
PHST- 2024/01/17 00:00 [accepted]
PHST- 2024/03/04 06:49 [medline]
PHST- 2024/03/04 06:48 [pubmed]
PHST- 2024/03/04 05:04 [entrez]
PHST- 2024/02/26 00:00 [pmc-release]
AID - 439001 [pii]
AID - 10.2147/JHC.S439001 [doi]
PST - epublish
SO  - J Hepatocell Carcinoma. 2024 Feb 26;11:399-409. doi: 10.2147/JHC.S439001. 
      eCollection 2024.